Nasopharyngeal Cancer - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 319
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N6085FA6FE7EN
Leaflet:

Download PDF Leaflet

Nasopharyngeal Cancer - Pipeline Review, H2 2017
Nasopharyngeal Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 13, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 2 and 5 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Nasopharyngeal Cancer - Overview
Nasopharyngeal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nasopharyngeal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Ambrx Inc
arGEN-X BV
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
BeiGene Ltd
BioDiem Ltd
Biomics Biotechnologies Co Ltd
Bristol-Myers Squibb Company
CBT Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Systimmune Inc
Tessa Therapeutics Pte Ltd
Theravectys SA
Viracta Therapeutics Inc
Yabao Pharmaceutical Group Co Ltd
Nasopharyngeal Cancer - Drug Profiles
alisertib - Drug Profile
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile
apatinib - Drug Profile
APG-1387 - Drug Profile
ARGX-110 - Drug Profile
ATA-129 - Drug Profile
atezolizumab - Drug Profile
avelumab - Drug Profile
azacitidine - Drug Profile
baltaleucel-T - Drug Profile
bevacizumab - Drug Profile
BGBA-317 - Drug Profile
CBT-501 - Drug Profile
Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile
Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer - Drug Profile
Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile
Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile
DC-120 - Drug Profile
donafenib - Drug Profile
durvalumab + tremelimumab - Drug Profile
EBViNT - Drug Profile
Epstein-Barr virus vaccine - Drug Profile
ficlatuzumab - Drug Profile
GSK-2849330 - Drug Profile
INCB-62079 - Drug Profile
ipilimumab - Drug Profile
ipilimumab + nivolumab - Drug Profile
JS-001 - Drug Profile
MAK-683 - Drug Profile
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
MVA vaccine - Drug Profile
NEO-212 - Drug Profile
nimotuzumab - Drug Profile
nivolumab - Drug Profile
OPB-111077 - Drug Profile
PDR-001 - Drug Profile
pembrolizumab - Drug Profile
SHR-1210 - Drug Profile
SIM-005A - Drug Profile
Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer - Drug Profile
SV-638 - Drug Profile
TT-10 - Drug Profile
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
Vaccine for Oncology - Drug Profile
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma - Drug Profile
VRx-3996 - Drug Profile
Nasopharyngeal Cancer - Dormant Projects
Nasopharyngeal Cancer - Discontinued Products
Nasopharyngeal Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Nasopharyngeal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2017
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2017
Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Celgene Corp, H2 2017
Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Nasopharyngeal Cancer - Pipeline by Incyte Corp, H2 2017
Nasopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H2 2017
Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2017
Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2017
Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Systimmune Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2017
Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017
Nasopharyngeal Cancer - Dormant Projects, H2 2017
Nasopharyngeal Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Nasopharyngeal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Advenchen Laboratories LLC
Ambrx Inc
arGEN-X BV
Atara Biotherapeutics Inc
AVEO Pharmaceuticals Inc
BeiGene Ltd
BioDiem Ltd
Biomics Biotechnologies Co Ltd
Bristol-Myers Squibb Company
CBT Pharmaceuticals Inc
Celgene Corp
Cell Medica Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Systimmune Inc
Tessa Therapeutics Pte Ltd
Theravectys SA
Viracta Therapeutics Inc
Yabao Pharmaceutical Group Co Ltd
Skip to top


Uterine Cancer - Pipeline Review, H1 2014 US$ 2,000.00 Apr, 2014 · 50 pages
Oropharyngeal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 May, 2017 · 158 pages
Gastric Cancer - Pipeline Review, H1 2017 US$ 2,500.00 May, 2017 · 982 pages
Esophageal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Apr, 2017 · 493 pages
Thyroid Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 383 pages

Ask Your Question

Nasopharyngeal Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: